American Association for Cancer Research
15357163mct150627-sup-153077_1_supp_3233182_nxzncd.xlsx (10.52 kB)

Table S1 from CD20-Targeting Immunotherapy Promotes Cellular Senescence in B-Cell Lymphoma

Download (10.52 kB)
posted on 2023-04-03, 15:49 authored by J. Henry M. Däbritz, Yong Yu, Maja Milanovic, Martin Schönlein, Mathias T. Rosenfeldt, Jan R. Dörr, Andreas M. Kaufmann, Bernd Dörken, Clemens A. Schmitt

Table S1 contains quantifications of BrdU/PI analyses depicted in main Figures 1 and 2.


German Cancer Consortium

Deutsche Krebshilfe



The CD20-targeting monoclonal antibody rituximab is an established component of immunochemotherapeutic regimens against B-cell lymphomas, where its coadministration with conventional anticancer agents has significantly improved long-term outcome. However, the cellular mechanisms by which rituximab exerts its antilymphoma activity are only partially understood. We show here that rituximab induces typical features of cellular senescence, a long-term growth arrest of viable cells with distinct biologic properties, in established B-cell lymphoma cell lines as well as primary transformed B cells. In addition, rituximab-based immunotherapy sensitized lymphoma cells to senescence induction by the chemotherapeutic compound adriamycin (a.k.a. doxorubicin), and, to a lesser extent, by the antimicrotubule agent vincristine. Anti-CD20 treatment further enhanced secretion of senescence-associated cytokines, and augmented the DNA damage response signaling cascade triggered by adriamycin. As the underlying prosenescence mechanism, we found intracellular reactive oxygen species (ROS) levels to be elevated in response to rituximab, and, in turn, the ROS scavenger N-acetylcysteine to largely abrogate rituximab-mediated senescence. Our results, further supported by gene set enrichment analyses in a clinical data set of chronic lymphocytic leukemia patient samples exposed to a rituximab-containing treatment regimen, provide important mechanistic insights into the biologic complexity of anti-CD20-evoked tumor responses, and unveil cellular senescence as a hitherto unrecognized effector principle of the antibody component in lymphoma immunochemotherapy. Mol Cancer Ther; 15(5); 1074–81. ©2016 AACR.